.png)
Agenzia Italiana del Farmaco
home
Highlights
-
28 Nov 2024
Independent clinical research
Promoting public research, AIFA invites stakeholders to propose research areas on medicines
AIFA, the first medicines agency in Europe including among its institutional objectives the promotion of scientific research, publishes a survey in order to receive proposals on research needs in the pharmacological field, available until January 15, 2025.
-
27 Nov 2024
Press releases
AIFA Board of Directors approves the reimbursability of 16 medicines
16 medicines (14 active ingredients), including orphan medicines for rare diseases (3), new molecules (7) and extensions of therapeutic indications (6).
-
25 Nov 2024
AIFA Notes
Second meeting of the Technical Committee for the revision of AIFA Notes and Therapeutic Plans
"The Technical-Scientific Director stated that ‘the Committee is actively contributing to developing proposals aimed to improve the prescribing activities of physicians on the territory".
-
12 Nov 2024
Press releases
AIFA published the 2023 OsMed Report “The use of medicines in Italy”
Appropriateness, therapeutic adherence and use of equivalent medicines improved, but there is considerable room for improvement.
News
10 Dec 2024
Companies Section
Election of digital address
09 Dec 2024
Safety of medicinal products
Direct communication with healthcare professionals on Metamizole-containing medicines
03 Dec 2024
Innovative medicinal products
Innovative medicines list: AIFA publishes November 2024 update
02 Dec 2024
Lists of Class A and Class H medicinal products
List of class A and H medicinal products at 16 April 2024
29 Nov 2024
Companies Section
New ACC application - Evolutionary changes
29 Nov 2024
Safety of medicinal products
Meeting highlights from the PRAC 25-28 November 2024
FarmaciLine
Per quesiti riguardanti efficacia, sicurezza e disponibilità dei farmaci
NUMERO VERDE
Services
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
